Zdrowie i gospodarka · 16/10/2018

FDA Releases Draft Guidance on Minimal Residual Disease for Hematologic Malignancies

The FDA has published a draft guidance to help pharmaceutical companies use minimal residual disease as a biomarker in clinical trials for certain blood cancers, aiming to support the development of new treatments.